TICKERNERD
Menu
FEMYFEMYHealthcare · Medical Instruments & Supplies

FEMY Stock Forecast: Femasys, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$1.44
+2.86% on the day

The 2 Wall Street analysts covering Femasys, Inc. hold a median 12-month price target of $17 — +1045.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 4 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$11.7M
Ticker Nerd rank
33/ 100
Median analyst target
$17
Analysts covering
2
Revenue$332K−18.9% y/y
Operating income−$5.1M
Net income−$4.5M
Free cash flow−$4.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.1%
1M
−29.8%
YTD
−87.5%
1Y
−89.5%
From 52W high
−93.1%
From 52W low
+9.1%
$1
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FEMY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Femasys, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
33/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
98
Size
90
Issuance
62
Revisions
47
Accruals
27
Momentum
21
Quality
13
Volatility
11
Value
11

Growth (98): Sales and profits are climbing, and climbing faster than before.

Value (11): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

FEMY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FEMY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26FEMYHigh $23Median $17Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $10Median $17High $23

The green dot is the last close — the median target sits +1045.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 Aug 2026Lake StreetMaintainsBuy$30 → $10
14 Aug 2026Maxim GroupMaintainsBuy$30 → $10
3 Mar 2026Lake StreetInitiatesBuy$1.50
3 Mar 2026Lake StreetInitiatesBuy—
20 Nov 2025Laidlaw & Co.InitiatesBuy—
11 Aug 2025HC Wainwright & Co.MaintainsBuy—
25 June 2025HC Wainwright & Co.ReiteratesBuy—
11 June 2025HC Wainwright & Co.ReiteratesBuy—
13 May 2025Jones TradingMaintainsBuy—
9 May 2025HC Wainwright & Co.MaintainsBuy—
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
19 Mar 2025HC Wainwright & Co.MaintainsBuy—
18 Mar 2025HC Wainwright & Co.ReiteratesBuy—
13 Mar 2025HC Wainwright & Co.ReiteratesBuy—
26 Feb 2025HC Wainwright & Co.ReiteratesBuy—
11 Feb 2025HC Wainwright & Co.ReiteratesBuy—
3 Dec 2024HC Wainwright & Co.ReiteratesBuy—
27 Nov 2024HC Wainwright & Co.ReiteratesBuy—
13 Nov 2024Chardan CapitalMaintainsBuy—
12 Nov 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

FEMY appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

FEMY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Femasys, Inc. returned −89.5% against +14.8% for the S&P 500, dividends included.

FEMY vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26FEMYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FEMY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Femasys, Inc. (FEMY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 78% of US stocks

Price / sales
5.1×

Cheaper than 23% of US stocks

Price / book
1.1×

Cheaper than 68% of US stocks

EV / EBITDA
−0.9×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
−18.9%

Higher than 12% of US stocks

Earnings growth (YoY)
−18.9%

Higher than 21% of US stocks

Gross margin
57.1%

Higher than 70% of US stocks

Operating margin
−1526.7%

Higher than 5% of US stocks

Net margin
62.0%

Higher than 97% of US stocks

Returns & dividend
Return on equity
−425.0%

Higher than 4% of US stocks

Return on assets
−84.2%

Higher than 4% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Femasys, Inc. (FEMY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Femasys, Inc. has a market value of $11.7M and an enterprise value of $15.0M.

  • Revenue in the twelve months to 30 June 2026: $2.3M. The latest quarter shrank 18.9% year on year.

  • Net income over the same four quarters: −$11.8M, a −511.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$18.2M.

  • Shares outstanding: 3.0M.

  • Trailing P/E: −0.1×; forward P/E: −0.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Femasys, Inc. employs 51 people — $45K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

FEMY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
FEMYFemasys, Inc.$11.7M33
NXGLNexGel, Inc.$12.3M15
CUPRCuprina Holdings (Cayman) Ltd.$11.3M4
RGNTRegentis Biomaterials Ltd.$9.3M8
BNGOBionano Genomics, Inc.$16.6M76
RVPRetractable Technologies, Inc.$16.9M59
LUCYInnovative Eyewear, Inc.$7.3M24

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Femasys, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FEMY news & analysis

Femasys Appoints John Moorhead to Board of Directors

GlobeNewsWire · 30 Oct 2026neutral

Femasys appointed John Moorhead to its Board of Directors as a board designee in connection with the company’s August 2026 private placement. Moorhead has more than two decades of experience in marketing, brand development, product innovation and finance.

Why it matters — FEMY watchers may note the board appointment and Moorhead’s background as the company adds a director connected with the private placement.

Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs

GlobeNewsWire · 20 Oct 2026positive

Femasys partnered with SandsRx Pharmacy as the first in a planned network of specialty pharmacy partnerships supporting the FemaSeed fertility portfolio launch to OB/GYNs. The partnership provides medication coordination and preferred pricing for OB/GYNs and their patients.

Why it matters — The partnership adds pharmacy coordination and pricing support to Femasys’ efforts to launch its FemaSeed portfolio through OB/GYNs.

Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control

GlobeNewsWire · 14 Oct 2026positive

Femasys doubled the number of enrolling sites in its FemBloc FINALE pivotal trial, bringing the total to 12 academic and private clinical sites across the U.S. The expansion broadens patient access as the company advances FemBloc toward potential FDA approval.

Why it matters — The expanded trial network is a development in Femasys’ effort to evaluate FemBloc for non-surgical permanent birth control and pursue potential FDA approval.

Femasys: Launch Is Funded. If The Sales Force Delivers, Then The Company Is In Tall Cotton.

Seeking Alpha · 14 Oct 2026positive

Seeking Alpha describes Femasys as a commercial-stage medtech company focused on OB/GYNs, with a $30 million PIPE recapitalization tying full funding to commercial traction. Its thesis centers on whether a lean sales force can convert OB/GYNs and health systems to the Fertility FastTrack suite.

Why it matters — FEMY watchers may focus on the recapitalization’s link to commercial traction and the sales force’s ability to drive adoption.

Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo

GlobeNewsWire · 8 Oct 2026neutral

Femasys announced it will exhibit at the ASRM 2026 Scientific Congress & Expo, taking place October 24–28 in Baltimore. The company plans to feature FemaSeed Intratubal Insemination and FemVue at booth #513.

Why it matters — The appearance gives FEMY watchers information about where and how the company plans to present its fertility and diagnostic products at the congress.

FAQ

Frequently asked questions about FEMY stock

What is the FEMY stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Femasys, Inc. have a median 12-month price target of $17, with estimates ranging from $10 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FEMY stock a buy right now?

Of the 2 analysts covering Femasys, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Femasys, Inc. 33 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FEMY?

As at 4 Nov 2026, Femasys, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).

Will FEMY stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +1045.8% from the last close, and Ticker Nerd's factor model ranks Femasys, Inc. 33 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FEMY stock forecast for 2030?

No analyst covering Femasys, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FEMY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $23 over the next 12 months.

How has FEMY stock performed over the past year?

Femasys, Inc. returned -89.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Femasys, Inc. do?

Femasys Inc. is a biomedical company focused on women’s reproductive health.

What is the latest news on FEMY?

The most recent item we track (GlobeNewsWire, 30 Oct 2026): "Femasys Appoints John Moorhead to Board of Directors". Femasys appointed John Moorhead to its Board of Directors as a board designee in connection with the company’s August 2026 private placement. Moorhead has more than two decades of experience in marketing, brand development, product innovation and finance.

Company

About Femasys, Inc.

Femasys Inc. is a biomedical company focused on women’s reproductive health. The company develops and commercializes accessible, minimally invasive, in-office therapeutic and diagnostic products designed to address unmet needs in fertility care, birth control, and gynecologic testing. Its portfolio includes FemVue for fallopian tube assessment, FemCath for selective tube evaluation, FemCerv for endocervical tissue sampling, FemBloc for non-surgical permanent birth control, and FemaSeed for assisted insemination. Femasys also offers related products and technologies used by physicians and women’s healthcare providers in office-based settings. Headquartered in Suwanee, Georgia, Femasys serves both U.S. and international markets with a focus on improving reproductive healthcare delivery.

CEO Ms. Kathy Lee-Sepsick M.B.A. · 51 employees · United States · https://femasys.com